MIRA net incomeQ2 2026-$1.21M
MIRA net income was -$1.21M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.54M a year earlier. For the full fiscal 2025 it was -$10.44M, compared with -$7.85M in fiscal 2024.
MIRA Pharmaceuticals Inc. (MIRA) financials
For the twelve months ended Jun 30, 2026, MIRA Pharmaceuticals Inc. reported -$9.48M of net income.
- Net income, TTM
- -$9.48M
- Cash
- $3.61M
- Market cap
- $26.1M
FY2022FY2025
MIRA revenue and earnings growth
MIRA EPSQ2 2026-$0.03
MIRA diluted EPS was -$0.03 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.35.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $1.72M | $3.31M | $1.57M | $2.35M |
| Selling, general and admin | $8.77M | $4.71M | $6.50M | $2.99M |
| Interest expense | - | -$165.7K | $3.46M | $10.3K |
| Net income | -$10.44M | -$7.85M | -$11.98M | -$7.06M |
| EPS, basic | -$1.35 | -$0.51 | -$0.85 | -$0.40 |
| EPS, diluted | -$1.35 | -$0.51 | -$0.85 | -$0.40 |
| Diluted shares | - | 15.4M | 13.9M | 17.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $6.35M | $2.83M | $4.60M | $351.0K |
| Short-term investments | $4.68M | - | - | - |
| Current assets | $11.06M | $2.89M | $4.86M | $494.4K |
| Total assets | $11.09M | $2.92M | $4.93M | $858.1K |
| Current liabilities | $702.1K | $723.3K | $558.1K | $1.37M |
| Total liabilities | $702.1K | $723.3K | $558.1K | $1.45M |
| Shareholders' equity | $10.39M | $2.20M | $4.37M | -$596.2K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$4.66M | -$5.56M | -$4.53M | -$5.60M |
| Financing cash flow | $8.18M | $3.79M | $8.78M | $3.15M |
| Stock-based compensation | $6.31M | $1.92M | $2.55M | $1.30M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $705.8K | $524.8K | $496.5K | $412.6K | $496.2K | $314.4K | $861.4K | $1.07M | $614.5K | $762.3K | $387.1K | $1.02M |
| Selling, general and admin | $450.3K | $578.7K | $5.33M | $904.3K | $1.05M | $1.49M | $1.58M | $1.01M | $1.12M | $1.01M | $2.67M | $2.14M |
| Interest expense | - | - | - | - | - | -$21.4K | -$38.1K | -$37.8K | -$39.4K | -$50.4K | $2.73M | $427.7K |
| Net income | -$1.21M | -$1.15M | -$5.98M | -$1.14M | -$1.54M | -$1.78M | -$2.40M | -$2.04M | -$1.69M | -$1.72M | -$5.79M | -$3.59M |
| EPS, basic | -$0.03 | -$0.03 | - | -$1.18 | -$0.09 | -$0.11 | -$0.11 | -$0.14 | -$0.11 | -$0.15 | - | -$0.26 |
| EPS, diluted | -$0.03 | -$0.03 | - | -$1.18 | -$0.09 | -$0.11 | -$0.11 | -$0.14 | -$0.11 | -$0.15 | - | -$0.26 |
| Diluted shares | - | - | - | 19.3M | 17.0M | 16.6M | - | 15.1M | 14.8M | 14.8M | - | 13.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.61M | $4.82M | $6.35M | $2.64M | $730.5K | $1.21M | $2.83M | $4.14M | $2.82M | $3.53M | $4.60M | $5.87M |
| Short-term investments | $4.50M | $4.59M | $4.68M | $4.89M | - | - | - | - | - | - | - | - |
| Current assets | $8.17M | $9.43M | $11.06M | $7.60M | $832.9K | $1.36M | $2.89M | $4.23M | $2.93M | $3.71M | $4.86M | $6.07M |
| Total assets | $8.20M | $9.46M | $11.09M | $7.63M | $868.3K | $1.40M | $2.92M | $4.27M | $3.02M | $3.81M | $4.93M | $9.02M |
| Current liabilities | $40.8K | $114.8K | $702.1K | $83.9K | $298.5K | $106.2K | $723.3K | $692.8K | $796.6K | $652.0K | $558.1K | $868.4K |
| Total liabilities | $40.8K | $114.8K | $702.1K | $83.9K | $298.5K | $106.2K | $723.3K | $692.8K | $796.6K | $652.0K | $558.1K | $902.9K |
| Shareholders' equity | $8.16M | $9.35M | $10.39M | $7.55M | $569.9K | $1.29M | $2.20M | $3.57M | $2.22M | $3.16M | $4.37M | $8.12M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.21M | -$1.20M | -$1.14M | -$1.10M | -$799.7K | -$1.63M | -$1.81M | -$1.84M | -$863.9K | -$1.05M | -$1.04M | -$1.76M |
| Financing cash flow | $0 | -$330.6K | $4.84M | $3.01M | $323.8K | $3.4K | $493.4K | $3.16M | $159.0K | -$24.3K | -$230.7K | $7.60M |
| Stock-based compensation | $21.9K | $107.6K | $4.56M | $390.8K | $489.6K | $874.8K | $546.8K | $269.0K | $604.8K | $500.2K | $213.8K | $1.45M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 200.08 | 82.16 | 15.75 | 90.53 | 2.79 | 12.86 | 3.99 | 6.11 | 3.68 | 5.70 | 8.70 | 6.99 |
Source: XBRL data MIRA Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MIRA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MIRA | - | - | -$9.48M | - | $26.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
MIRA FAQ
4 questionsIs MIRA profitable?
No. MIRA Pharmaceuticals Inc. reported a net loss of $9.48M for the twelve months ended Jun 30, 2026.How much cash and debt does MIRA have?
MIRA Pharmaceuticals Inc. reported $3.61M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did MIRA last report financial results?
The latest statements here come from MIRA Pharmaceuticals Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this MIRA financial data come from?
Quantisnow builds these statements from the structured XBRL data MIRA Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.